To determine if the investigational treatment BAN2401 is superior to a placebo in terms of maintaining normal cognitive (memory and thinking) abilities, and how effective it is in reducing levels of amyloid and tau plaques in the brain associated with the development of Alzheimer’s disease.
Eligible participants will be randomly assigned to one of two groups: one that will receive the investigational medication, BAN2401, or one that will receive a placebo.
Participants will be monitored for 4 years.
Men and women ages 55 – 80
Have a partner to accompany you to study appointments